PTC Therapeutics Grants Stock Options and RSUs to New Employees
PTC Therapeutics announced the issuance of stock options and restricted stock units (RSUs) to 37 new employees as part of their compensation, under Nasdaq's inducement grant exception.
PTC Therapeutics reported on September 25, 2026, that it approved non-statutory stock options for an aggregate of 51,270 shares of common stock and 37,995 restricted stock units (RSUs) to 37 new employees. These awards were made as a component of new hires' employment compensation under the Nasdaq inducement grant exception.
The stock options have an exercise price of $65.96 per share, the closing price on September 22, 2026. The options have a 10-year term and vest over four years. The RSUs also vest over a four-year period. These grants are intended to attract and retain new talent to the company.
The inducement grants were approved by PTC's Compensation Committee on September 22, 2026. PTC Therapeutics is a global biopharmaceutical company focused on the discovery, development, and commercialization of therapies for rare disorders.
The company aims to provide patients with rare diseases access to differentiated therapies and optimize value for stakeholders by leveraging its scientific expertise and commercial infrastructure.